Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05967455 · ClinicalTrials.gov registry record · Phase 1
Homologous Re-infection With Dengue 1 or Dengue 3
A Phase 1 study, sponsored by State University of New York - Upstate Medical University.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT05967455: Completed Phase 1 study, sponsored by State University of New York - Upstate Medical University.
NCT05967455 is a Phase 1 study that has completed, run by State University of New York - Upstate Medical University. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05967455, a Phase 1 study, has completed, sponsored by State University of New York - Upstate Medical University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
Previous studies with one dengue infection in a controlled environment at Upstate generated data that has been important in understanding the clinical signs and symptoms and how a person's body reacts to dengue infection over time. This has helped investigators compare what is seen in the clinic to what is seen in areas where dengue is prevalent. The investigators want to collect similar information when a person gets the same dengue twice in a controlled environment with the hope that this will lead them to a better understanding of the disease. New participants * will receive one inoculation of dengue and then return to the clinic or be contacted by phone over 6 months; * will receive a second inoculation after 6 months and return to the clinic or be contacted by phone for three more months; * will collect saliva at home; * will allow the study team to collect blood and saliva at the clinic visits. Participants who have been in previous dengue inoculation studies at SUNY Upstate * will receive one inoculation of dengue and then return to the clinic or be contacted by phone over 6 months; * will collect saliva at home; * will allow the study team to collect blood and saliva at the clinic visits. All participants will be seen in the clinic every other day for the first three weeks after any inoculation.
Primary Outcome
Number of solicited symptoms
Interventions
- BIOLOGICAL Dengue virus 1 Live Virus Human Challenge (DENV-1-LVHC)
- BIOLOGICAL Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2023-10-30 |
| Est. Completion | 2024-08-26 |
| Phase | Phase 1 |
What the finished NCT05967455 record still lists
NCT05967455 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Dengue virus 1 Live Virus Human Challenge (DENV-1-LVHC) is the first listed.
NCT05967455 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05967455 about?
NCT05967455 is a clinical study titled "Homologous Re-infection With Dengue 1 or Dengue 3". Previous studies with one dengue infection in a controlled environment at Upstate generated data that has been important in understanding the clinical signs and symptoms and how a person's body reacts to dengue infection over time. This has helped investigators compare what is seen in the clinic to ...
What is the current status of trial NCT05967455?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2023-10-30. Estimated completion is 2024-08-26.
What interventions are being tested in trial NCT05967455?
The interventions under investigation include: Dengue virus 1 Live Virus Human Challenge (DENV-1-LVHC) (BIOLOGICAL), Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05967455?
This trial is sponsored by State University of New York - Upstate Medical University, which has 113 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05967455's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI